(Reuters)—U.S. President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House. The order under discussion would be much broader than the Administration’s previously disclosed proposal to lower…
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Drug Makers Met with Trump to Argue against Senate Pricing Bill
(Reuters)—The main pharmaceutical industry lobbying group said on Thursday it and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices. The White House, which has said it backs the legislation, has promised to bring down drug prices for U.S. consumers, an…

RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
Practical, Diverse Knowledge: A Preview of 2019’s ARP Sessions
From insights into mentoring and statistics to integrating virtual reality into a patient’s rehab—the educational sessions offered during the ACR/ARP Annual Meeting will be practical, yet innovative and inspiring…

Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…
Top 2020 Contenders Snipe over Healthcare Policy
WASHINGTON (Reuters) – Democratic presidential front-runner Joe Biden and rival Bernie Sanders are waging a public battle this week over universal healthcare, staking out competing turf on an issue that has become the most divisive in the party’s primary campaign. The sniping between the two White House contenders, highlighted on Wednesday when Sanders delivered a…

The ACR & ARP Fight Step Therapy on Capitol Hill
Step therapy (or fail first) policies introduce significant barriers to access to effective treatments for patients with rheumatic diseases. They also impose significant administrative and cost burdens on providers and practices. The ACR and ARP are advocating state governments, Congress and regulatory agencies limit the impact of these policies on access to care by creating…
The Rheumatology Research Foundation Announces Award Recipients
On July 1, 2019, the Foundation awarded more than 80 grants to a wide range of rheumatology trainees, professionals and institutions. The recipients will receive funding for essential training and career development, as well as for innovative research projects. Their applications were closely examined by experts in different areas of the field to ensure awards…

Ethics Forum: Beware Your Intellectual Conflicts of Interest
A senior rheumatologist with extensive experience in the management of systemic lupus erythematosus is asked to help draft clinical guidelines for the treatment of lupus nephritis. Neither she nor her family members receive grant funding nor does she consult with any pharmaceutical or biotechnology companies. She does have strong clinical opinions based on current evidence…

In Wake of Lupus Trial Failure, New Research Attacks From Many Angles
CHICAGO—When Richard Furie, MD, was first asked to speak about lupus at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7, organizers suggested he discuss low disease activity and classification criteria. But Dr. Furie, a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y., and a veteran investigator…
- « Previous Page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- …
- 305
- Next Page »